Hard To Treat Diseases, Incorporated

Hard To Treat Diseases, Incorporated

May 17, 2006 09:35 ET

Hard To Treat Diseases, Incorporated Announces: Involvement Of Dr. Leland Shapiro

DELRAY BEACH, FLORIDA--(CCNMatthews - May 17, 2006) - Hard To Treat Diseases, Incorporated (HTTD) (PINK SHEETS:HTDS) announces that Dr. Leland Shapiro will be instrumental in the process of doing a deal with a major pharmaceutical company.

Dr Shapiro has been the principal investigator for conducting the majority of experiments and lab research that culminated in HTTD's current patent applications and testing results. He has established protocols that define specific areas for additional testing that will be included in the presentations to drug companies.

The process of dealing with a pharmaceutical company involves numerous steps, including a presentation that explains substantiated findings and assets and face-to-face scientific meetings. Dr. Shapiro will be actively involved in both steps.

HTTD's CEO Colm J. King states, "Dr. Shapiro is an experienced medical and scientific research professional. He can discuss the testing results included in HTTD's patent applications, the detailed protocols he has established and the potential of the Companies patent rights better than any other individual. His involvement on the Companies expert team in discussing patent application discoveries and developments is a valuable asset."

The Company is aggressively moving forward by positioning its assets for acquisition by a major drug company that specializes in oncology and infectious diseases. An expert team is focused on the process of presentations and negotiations for the benefit of patients and shareholders.

Additional information is available on the Company's website at: www.htdsotc.com and a presentation regarding HTTD by Mr. King is available at the following link: http://www.publiccoreport.net/featured/HTDS/company.asp

Cautionary Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Contact Information

  • Hard to Treat Diseases, Incorporated
    Colm J. King
    (561) 278-7856